Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alentis Therapeutics
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
- Other Names / Subsidiaries
- ALENTIS Therapeutics Ltd